A blue kidney, although very rare, can be encountered upon a live kidney donor. Literature has shown hemosiderin deposits, lipofuscin pigment, and melanosis as possible reasons. We report on a 37-year-old woman who wished to donate a kidney to her husband. The donor's preoperative biochemistry and imaging tests showed normal renal function. During the laparoscopic left kidney nephrectomy, the kidney was observed to be blue in color. Perioperatively, Doppler ultrasonography was used to rule out vascular reasons, and a wedge biopsy was performed. The other kidney was also explored, and it turned out to be blue as well. Histopathological analysis showed melanosis in the tubules without malignity or pathologic changes in the glomeruli, the interstitium, or the vessels. Even though some causes of blue kidney may result in impairment of the renal function, after the necessary tests show no signs of malignity and functional impairment, a blue-colored kidney may be suitable for transplantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2019.01.091 | DOI Listing |
Beijing Da Xue Xue Bao Yi Xue Ban
February 2025
Department of Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.
This study reports the diagnosis and treatment of a 26-year-old pregnant woman with severe malnutrition combined with acute pyelonephritis causing sepsis, refractory septic shock and multiple organ failure. A female patient, 26 years old, was admitted to hospital mainly due to "menelipsis for more than 19 weeks, nausea and vomiting for 20 days, fever with fatigue for 3 days". At the end of 19 weeks of intrauterine pregnancy, the patient presented with fever accompanied by urinary tract irritation.
View Article and Find Full Text PDFBioorg Chem
January 2025
Department of Radiology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000 China; Precision Imaging and Intelligent Analysis Key Laboratory of Luzhou City, Luzhou 646000 China. Electronic address:
Hypochlorite anion (ClO) is closely associated with cancer development and progression, necessitating precise monitoring of ClO in tumor sites, and Cyclooxygenase-2 (COX-2 is highly expressed in tumor cells. So we rationally designed two ClO-specific responsive fluorescent probes COX2-ClO1 and COX2-ClO2, using indomethacin (IMC) as the COX-2 targeting moiety and methylene blue as fluorophore unit. Both probes exhibited high selectivity and sensitivity towards ClO in the in vitro solution assays and possess excellent biocompatibility in cellular experiments.
View Article and Find Full Text PDFBiosensors (Basel)
January 2025
CBQF-Centro de Biotecnologia e Química Fina, Laboratório Associado, Universidade Católica Portuguesa, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal.
Chronic Kidney Disease (CKD) is a disorder that affects over 10% of the global population, and that would benefit from innovative methodologies that would provide early detection. Since it has been reported that there are high levels of urease in CKD patients' saliva, this sample is a promising non-invasive alternative to blood for CKD detection and monitoring. This work introduces a novel 3D µPAD for quantifying urease activity in saliva in a range of 0.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Sanya Institute of Breeding and Multiplication, School of Marine Biology and Fisheries, Collaborative Innovation Center of Marine Science and Technology, Hainan University, China; Engineering Research Center of Hainan Province for Blue Carbonand Coastal Wetland Conservation and Restoration, China; International Joint Research Center of Hainan Province for Blue Carbon and Coastal Wetland, China. Electronic address:
Tumour necrosis factor (TNF) is one of the most pivotal factors of the TNF family and plays an essential biological role in immunity. However, the antibacterial function and mechanism of TNFα in teleosts are relatively poorly understood. In this study, a novel TNFα from Trachinotus ovatus (TroTNFα) was characterized.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!